VERV - Verve Therapeutics, Inc.
IEX Last Trade
5.76
-1.385 -24.045%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:21:31 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$7.14
-1.39
-19.38%
Fundamental analysis
13%
Profitability
8%
Dept financing
6%
Liquidity
75%
Performance
5%
Performance
5 Days
0.52%
1 Month
9.07%
3 Months
20.96%
6 Months
10.33%
1 Year
-59.62%
2 Year
-67.68%
Key data
Stock price
$5.76
DAY RANGE
$5.94 - $7.14
52 WEEK RANGE
$4.55 - $19.34
52 WEEK CHANGE
-$60.67
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Sekar Kathiresan
Region: US
Website: vervetx.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vervetx.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Verve Therapeutics, Inc. engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver.
Recent news